Concepts (143)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Parkinson Disease | 23 | 2020 | 591 | 3.410 |
Why?
|
| Hallucinations | 9 | 2023 | 38 | 1.770 |
Why?
|
| Emotions | 2 | 2015 | 69 | 0.500 |
Why?
|
| Visual Pathways | 2 | 2014 | 2 | 0.490 |
Why?
|
| Amygdala | 1 | 2015 | 34 | 0.470 |
Why?
|
| Blindness | 1 | 2014 | 7 | 0.430 |
Why?
|
| Brain | 3 | 2023 | 1202 | 0.420 |
Why?
|
| Humans | 28 | 2023 | 22823 | 0.380 |
Why?
|
| Contrast Sensitivity | 3 | 2002 | 6 | 0.380 |
Why?
|
| Placebo Effect | 1 | 2008 | 10 | 0.290 |
Why?
|
| Placebos | 1 | 2008 | 63 | 0.290 |
Why?
|
| REM Sleep Behavior Disorder | 1 | 2008 | 2 | 0.290 |
Why?
|
| Tauopathies | 1 | 2008 | 13 | 0.280 |
Why?
|
| Depressive Disorder | 1 | 2008 | 163 | 0.270 |
Why?
|
| Fetal Tissue Transplantation | 2 | 2000 | 22 | 0.260 |
Why?
|
| Dystonia | 3 | 1997 | 10 | 0.250 |
Why?
|
| Head | 1 | 2006 | 17 | 0.240 |
Why?
|
| Myositis | 1 | 2006 | 16 | 0.240 |
Why?
|
| Multiple System Atrophy | 1 | 2006 | 26 | 0.240 |
Why?
|
| Pain | 1 | 2008 | 326 | 0.240 |
Why?
|
| Visual Perception | 2 | 2005 | 21 | 0.240 |
Why?
|
| Color Vision Defects | 2 | 2002 | 3 | 0.230 |
Why?
|
| Age of Onset | 2 | 2003 | 71 | 0.230 |
Why?
|
| Brain Chemistry | 1 | 2005 | 33 | 0.220 |
Why?
|
| Cerebral Cortex | 2 | 2020 | 125 | 0.220 |
Why?
|
| Sick Role | 1 | 2003 | 15 | 0.200 |
Why?
|
| Vision Disorders | 2 | 2005 | 19 | 0.200 |
Why?
|
| Models, Biological | 1 | 2005 | 283 | 0.200 |
Why?
|
| Aged | 12 | 2008 | 7412 | 0.200 |
Why?
|
| Attention Deficit Disorder with Hyperactivity | 1 | 2023 | 31 | 0.200 |
Why?
|
| Middle Aged | 11 | 2008 | 7873 | 0.190 |
Why?
|
| Space Perception | 1 | 2002 | 19 | 0.190 |
Why?
|
| Adaptation, Psychological | 1 | 2003 | 165 | 0.190 |
Why?
|
| Levodopa | 4 | 2009 | 34 | 0.180 |
Why?
|
| Subthalamic Nucleus | 1 | 2000 | 19 | 0.160 |
Why?
|
| Electric Stimulation Therapy | 1 | 2000 | 39 | 0.160 |
Why?
|
| Axons | 1 | 2020 | 24 | 0.160 |
Why?
|
| Mitochondria | 1 | 2020 | 52 | 0.160 |
Why?
|
| Adrenal Glands | 1 | 2000 | 10 | 0.160 |
Why?
|
| Male | 12 | 2008 | 12400 | 0.160 |
Why?
|
| Movement Disorders | 2 | 1998 | 57 | 0.160 |
Why?
|
| Corpus Striatum | 1 | 2000 | 63 | 0.160 |
Why?
|
| Huntington Disease | 1 | 2000 | 45 | 0.160 |
Why?
|
| Sleep Wake Disorders | 3 | 2009 | 108 | 0.160 |
Why?
|
| Botulinum Toxins | 2 | 1997 | 8 | 0.150 |
Why?
|
| Substantia Nigra | 1 | 2000 | 101 | 0.150 |
Why?
|
| Biological Evolution | 1 | 2019 | 9 | 0.150 |
Why?
|
| Psychoses, Substance-Induced | 1 | 1998 | 4 | 0.150 |
Why?
|
| Color Perception | 1 | 1998 | 5 | 0.150 |
Why?
|
| Mental Disorders | 1 | 2000 | 134 | 0.140 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 1 | 1998 | 15 | 0.140 |
Why?
|
| Neurons | 1 | 2020 | 273 | 0.140 |
Why?
|
| Muscle Relaxants, Central | 1 | 1997 | 3 | 0.140 |
Why?
|
| Baclofen | 1 | 1997 | 3 | 0.140 |
Why?
|
| Cytochrome P-450 CYP2D6 | 1 | 1996 | 1 | 0.130 |
Why?
|
| Genes | 1 | 1996 | 6 | 0.130 |
Why?
|
| Follow-Up Studies | 4 | 2006 | 1412 | 0.130 |
Why?
|
| Globus Pallidus | 1 | 1996 | 10 | 0.120 |
Why?
|
| Genetic Variation | 1 | 1996 | 68 | 0.120 |
Why?
|
| Phylogeny | 1 | 2015 | 44 | 0.120 |
Why?
|
| Nervous System Diseases | 1 | 1997 | 99 | 0.120 |
Why?
|
| Female | 9 | 2008 | 12904 | 0.110 |
Why?
|
| Superior Colliculi | 1 | 2014 | 1 | 0.110 |
Why?
|
| Magnetic Resonance Imaging | 2 | 2009 | 858 | 0.100 |
Why?
|
| Basal Ganglia | 2 | 2008 | 13 | 0.100 |
Why?
|
| Lewy Bodies | 1 | 2014 | 146 | 0.100 |
Why?
|
| Adrenal Medulla | 1 | 1993 | 7 | 0.100 |
Why?
|
| Thalamus | 1 | 1992 | 15 | 0.090 |
Why?
|
| Dopamine Agents | 1 | 1992 | 11 | 0.090 |
Why?
|
| Dopamine | 2 | 2008 | 77 | 0.090 |
Why?
|
| Risk Factors | 3 | 2005 | 1966 | 0.090 |
Why?
|
| Antiparkinson Agents | 2 | 2003 | 41 | 0.080 |
Why?
|
| Vision Tests | 2 | 2002 | 4 | 0.080 |
Why?
|
| Cognition Disorders | 2 | 2009 | 691 | 0.080 |
Why?
|
| Disease Progression | 2 | 2003 | 521 | 0.080 |
Why?
|
| Illusions | 1 | 2009 | 1 | 0.080 |
Why?
|
| Cholinesterase Inhibitors | 1 | 2009 | 12 | 0.080 |
Why?
|
| Neurotransmitter Agents | 1 | 2009 | 13 | 0.080 |
Why?
|
| Antipsychotic Agents | 1 | 2009 | 50 | 0.070 |
Why?
|
| Opioid Peptides | 1 | 2008 | 10 | 0.070 |
Why?
|
| Meta-Analysis as Topic | 1 | 2008 | 23 | 0.070 |
Why?
|
| Supranuclear Palsy, Progressive | 1 | 2008 | 21 | 0.070 |
Why?
|
| Positron-Emission Tomography | 1 | 2008 | 72 | 0.070 |
Why?
|
| Major Histocompatibility Complex | 1 | 2006 | 4 | 0.060 |
Why?
|
| Animals | 2 | 2009 | 3255 | 0.060 |
Why?
|
| Electromyography | 1 | 2006 | 67 | 0.060 |
Why?
|
| Biopsy | 1 | 2006 | 186 | 0.060 |
Why?
|
| Dementia | 1 | 2008 | 388 | 0.050 |
Why?
|
| Adult | 3 | 2003 | 6896 | 0.050 |
Why?
|
| Reality Testing | 1 | 2003 | 1 | 0.050 |
Why?
|
| Muscle, Skeletal | 1 | 2006 | 323 | 0.050 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2006 | 572 | 0.050 |
Why?
|
| Self Care | 1 | 2003 | 85 | 0.050 |
Why?
|
| Odds Ratio | 1 | 2003 | 217 | 0.050 |
Why?
|
| Social Support | 1 | 2003 | 174 | 0.050 |
Why?
|
| Logistic Models | 1 | 2003 | 350 | 0.050 |
Why?
|
| Prevalence | 1 | 2003 | 375 | 0.050 |
Why?
|
| Case-Control Studies | 1 | 2003 | 481 | 0.050 |
Why?
|
| Comorbidity | 1 | 2003 | 426 | 0.040 |
Why?
|
| Databases, Factual | 1 | 2003 | 307 | 0.040 |
Why?
|
| Risk Assessment | 1 | 2003 | 546 | 0.040 |
Why?
|
| Aged, 80 and over | 1 | 2008 | 3717 | 0.040 |
Why?
|
| Syndrome | 1 | 2000 | 66 | 0.040 |
Why?
|
| Severity of Illness Index | 1 | 2003 | 795 | 0.040 |
Why?
|
| Sleep, REM | 1 | 1998 | 13 | 0.040 |
Why?
|
| Wounds and Injuries | 1 | 1998 | 34 | 0.040 |
Why?
|
| Violence | 1 | 1998 | 34 | 0.040 |
Why?
|
| Prospective Studies | 1 | 2002 | 1487 | 0.030 |
Why?
|
| Botulinum Toxins, Type A | 1 | 1997 | 6 | 0.030 |
Why?
|
| Infusion Pumps, Implantable | 1 | 1997 | 5 | 0.030 |
Why?
|
| Catheters, Indwelling | 1 | 1997 | 20 | 0.030 |
Why?
|
| Drug Therapy, Combination | 1 | 1997 | 162 | 0.030 |
Why?
|
| Muscle Spasticity | 1 | 1997 | 4 | 0.030 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 1997 | 312 | 0.030 |
Why?
|
| Motor Neurons | 1 | 1996 | 15 | 0.030 |
Why?
|
| Models, Neurological | 1 | 1996 | 19 | 0.030 |
Why?
|
| Models, Anatomic | 1 | 1996 | 32 | 0.030 |
Why?
|
| Registries | 1 | 1996 | 173 | 0.030 |
Why?
|
| Longitudinal Studies | 1 | 1997 | 1047 | 0.030 |
Why?
|
| Tomography, Emission-Computed | 1 | 1993 | 10 | 0.020 |
Why?
|
| Oxidopamine | 1 | 1993 | 10 | 0.020 |
Why?
|
| 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine | 1 | 1993 | 16 | 0.020 |
Why?
|
| Stereotaxic Techniques | 1 | 1993 | 14 | 0.020 |
Why?
|
| Lisuride | 1 | 1992 | 1 | 0.020 |
Why?
|
| Methylcellulose | 1 | 1992 | 1 | 0.020 |
Why?
|
| Pergolide | 1 | 1992 | 2 | 0.020 |
Why?
|
| Apomorphine | 1 | 1992 | 3 | 0.020 |
Why?
|
| Bromocriptine | 1 | 1992 | 3 | 0.020 |
Why?
|
| Lactose | 1 | 1992 | 3 | 0.020 |
Why?
|
| Oxazines | 1 | 1992 | 5 | 0.020 |
Why?
|
| Receptors, Dopamine | 1 | 1992 | 8 | 0.020 |
Why?
|
| Functional Laterality | 1 | 1992 | 54 | 0.020 |
Why?
|
| Analysis of Variance | 1 | 1992 | 228 | 0.020 |
Why?
|
| Postoperative Period | 1 | 1992 | 238 | 0.020 |
Why?
|
| Tremor | 1 | 1992 | 93 | 0.020 |
Why?
|
| Parasympatholytics | 1 | 1990 | 3 | 0.020 |
Why?
|
| Dopamine Antagonists | 1 | 1990 | 5 | 0.020 |
Why?
|
| Neuromuscular Diseases | 1 | 1990 | 5 | 0.020 |
Why?
|
| Neurosurgery | 1 | 1990 | 32 | 0.020 |
Why?
|
| Diagnosis, Differential | 1 | 1990 | 309 | 0.020 |
Why?
|
| Time Factors | 1 | 1992 | 1258 | 0.020 |
Why?
|
| Caregivers | 1 | 1998 | 185 | 0.010 |
Why?
|
| Surveys and Questionnaires | 1 | 1998 | 1019 | 0.010 |
Why?
|